相关实验视频
Updated: May 10, 2025
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
抑郁症状与粉样蛋白阳性成年人积率相关
Daniel Talmasov1, Aubrey S Johnson2, Patrick J Brown3
1Department of Neurology (DT, ASJ, FAP, PJL, KSM, ADNI), Columbia University Irving Medical Center, New York, NY; Department of Psychiatry (DT, PJB, JMM), Columbia University Irving Medical Center, New York, NY.
概括
抑郁症与阿密洛因阳性阿尔茨海默氏病 (AD) 患者的大脑积速度更快有关. 这表明抑郁症可能表明阿尔茨海默病的进展,并保证进一步的研究作为可修改的危险因素.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 阿尔茨海默病的研究研究.
- 老年精神病学是一门精神病学专业.
背景情况:
- 抑郁症是阿尔茨海默病 (AD) 中常见的并发症.
- 在阿尔茨海默病中,抑郁症状与加速的认知衰退和增加的病理有关.
- 了解抑郁症和AD生物标志物之间的关系对于疾病管理至关重要.
研究的目的:
- 调查抑郁症状与老年人积率之间的关联.
- 为了检查老年抑郁量表 (GDS) 的得分是否与叶的积相相关.
- 在阿尔茨海默病神经成像倡议 (ADNI) 队列中,在粉样蛋白阳性的背景下探索这种关系.
主要方法:
- 利用了阿尔茨海默病神经成像计划 (ADNI) 数据库中的303名参与者的数据.
- 评估了从2015年至2022年的序列[18F]-flortaucipir tau正子发射断层扫描 (PET) 扫描结果.
- 相关的老年抑郁量表 (GDS) 分数与叶区域的年化陶积累率相关,并对共变量进行调整.
主要成果:
- 在老年抑郁量表 (GDS) 评分和年化积累率之间发现了正相关性.
- 这种关联在粉样蛋白阳性参与者中显著.
- 在粉样蛋白阴性参与者中没有观察到显著的相关性.
结论:
- 抑郁症状与阿尔茨海默病的粉样蛋白阳性个体的加速tau积累有关.
- 抑郁症可能是阿尔茨海默氏症病理进展的指标.
- 进一步研究抑郁症作为阿尔茨海默病的可修改风险因素是有必要的.
相关概念视频
01:26Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128